Alere (NYSE:ALR) had an volatile session and gained 0.1 points till last call. The price was at $42.78, gaining 0.23% till the last intraday data. The total uptick value was $2.52 million while the total downtick value was $4.36 million. The shares saw a net money flow of $(-1.84) million and the up/down ratio stood at 0.58. The stock has seen a change of of -0.12% for the week. The share had a block transaction during the course of trading in which the net money flow was $(-1.65) million. Almost $0 million were received in upticks and approximately $1.65 million were lost in downticks, thereby giving the up/down ratio of 0.
Currently the company Insiders own 1.93% of Alere shares according to the proxy statements. Institutional Investors own 91.81% of Alere shares. On the companys insider trading activities,The officer (VP, Chief Accounting Officer) of Alere Inc., Flakne Carla sold 10,000 shares at $42.44 on January 16, 2015. The Insider selling transaction had a total value worth of $424,400. The Insider information was disclosed with the Securities and Exchange Commission in a Form 4 filing.
Alere (NYSE:ALR) stock ended Monday session in the red zone in a volatile trading. The stock closed down 0.35 points or 0.82% at $42.43 with 376,416 shares getting traded. Post opening the session at $42.78, the shares hit an intraday low of $42.41 and an intraday high of $43.0399 and the price was in this range throughout the day. The company has a market cap of $3,660 million and the number of outstanding shares have been calculated to be 86,256,820 shares. The 52-week high of Alere (NYSE:ALR) is $55.99 and the 52-week low is $31.96.
Many analysts have stated their opinion on the company shares. Equity Analysts at the Craig-Hallum upgrades the rating on Alere (NYSE:ALR). The brokerage firm has issued a Buy rating on the shares. The shares were previously rated Hold. The rating by the firm was issued on April 29, 2016.
Alere Inc. is a provider of health information through diagnostic tests. The Company operates through professional diagnostics, patient self-testing, consumer diagnostics and, corporate and other segments. The professional diagnostics segment includes an array of diagnostic test products and other in vitro diagnostic tests marketed to medical professionals and laboratories for detection of diseases and conditions within its areas of focus. The patient-self testing segment provides services designed to provide physicians with actionable data that allow them to make decisions in real time, deliver care, and put the individuals they treat on a pathway to better health. The consumer diagnostics segment consists primarily of manufacturing operations related to its role as the exclusive manufacturer of products for SPD Swiss Precision Diagnostics (SPD), its 50/50 joint venture with The Procter & Gamble Company (P&G).